Efficacy and Safety of Finerenone in Patients with Idiopathic Membranous Nephropathy: A Multicentre, Prospective-Retrospective Real-World Study
In combination with ACEIs or ARBs, finerenone appeared to reduce proteinuria in IMN patients with or without immunosuppressive therapy. Serum potassium did not exceed 5.5 mmol/L in any cases.
Authors
- Xiang-hui Chen
- E Jing
- Akhmedova Nilufar Sharipovna
- Jiamei Lu
- Xiao‐Yong Yu
- Min Qi (ORCID: https://orcid.org/0000-0003-4109-3672)
- Dan-Na Ma
- Yan Li
- Rong-Guo Fu
- Xiao-tao Ma
- Chieh Suai Tan
- Yu-Lin Zhu
- Jian-Peng Zhang
- Zhao Chen
- Yang Wei
- Zhe Kang
- Jason Choo
- Jia-Yi Li
Institutions
- Singapore General Hospital (SG)
- China International Science and Technology Cooperation (CN)
- Bukhara State Medical Institute named after Abu Ali ibn Sino (UZ)
- The People's Hospital Tongling (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Shaanxi Provincial Hospital of Traditional Chinese Medicine (CN)
- The Fourth People's Hospital of Ningxia Hui Autonomous Region (CN)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1159/000550311
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00